292 related articles for article (PubMed ID: 29562821)
41. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
42. The cellular labile iron pool and intracellular ferritin in K562 cells.
Konijn AM; Glickstein H; Vaisman B; Meyron-Holtz EG; Slotki IN; Cabantchik ZI
Blood; 1999 Sep; 94(6):2128-34. PubMed ID: 10477743
[TBL] [Abstract][Full Text] [Related]
43. Intracellular Iron Chelation Modulates the Macrophage Iron Phenotype with Consequences on Tumor Progression.
Mertens C; Akam EA; Rehwald C; Brüne B; Tomat E; Jung M
PLoS One; 2016; 11(11):e0166164. PubMed ID: 27806101
[TBL] [Abstract][Full Text] [Related]
44. Iron and oxidative stress in cardiomyopathy in thalassemia.
Berdoukas V; Coates TD; Cabantchik ZI
Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
[TBL] [Abstract][Full Text] [Related]
45. Antineoplastic drugs that interfere with iron metabolism in cancer cells.
Head JF; Wang F; Elliott RL
Adv Enzyme Regul; 1997; 37():147-69. PubMed ID: 9381969
[TBL] [Abstract][Full Text] [Related]
46. Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells.
Pahl PM; Horwitz MA; Horwitz KB; Horwitz LD
Breast Cancer Res Treat; 2001 Sep; 69(1):69-79. PubMed ID: 11759830
[TBL] [Abstract][Full Text] [Related]
47. Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron.
Haney SL; Varney ML; Safranek HR; Chhonker YS; G-Dayanandan N; Talmon G; Murry DJ; Wiemer AJ; Wright DL; Holstein SA
Leuk Res; 2019 Feb; 77():17-27. PubMed ID: 30612055
[TBL] [Abstract][Full Text] [Related]
48. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL
Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908
[TBL] [Abstract][Full Text] [Related]
49. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells.
Kulp KS; Green SL; Vulliet PR
Exp Cell Res; 1996 Nov; 229(1):60-8. PubMed ID: 8940249
[TBL] [Abstract][Full Text] [Related]
50. Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas.
Jiang XP; Elliott RL; Head JF
Anticancer Res; 2010 Mar; 30(3):759-65. PubMed ID: 20392994
[TBL] [Abstract][Full Text] [Related]
51. Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.
Benadiba J; Rosilio C; Nebout M; Heimeroth V; Neffati Z; Popa A; Mary D; Griessinger E; Imbert V; Sirvent N; Peyron JF
Leuk Lymphoma; 2017 Jun; 58(6):1433-1445. PubMed ID: 27736268
[TBL] [Abstract][Full Text] [Related]
52. The regulation of iron metabolism by hepcidin contributes to unloading-induced bone loss.
Xu Z; Sun W; Li Y; Ling S; Zhao C; Zhong G; Zhao D; Song J; Song H; Li J; You L; Nie G; Chang Y; Li Y
Bone; 2017 Jan; 94():152-161. PubMed ID: 27686598
[TBL] [Abstract][Full Text] [Related]
53. Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats.
Ishizaka N; Saito K; Mori I; Matsuzaki G; Ohno M; Nagai R
Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2282-8. PubMed ID: 16100038
[TBL] [Abstract][Full Text] [Related]
54. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
Kim JL; Lee DH; Na YJ; Kim BR; Jeong YA; Lee SI; Kang S; Joung SY; Lee SY; Oh SC; Min BW
Tumour Biol; 2016 Jul; 37(7):9709-19. PubMed ID: 26803514
[TBL] [Abstract][Full Text] [Related]
55. Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool.
Jamnongkan W; Thanan R; Techasen A; Namwat N; Loilome W; Intarawichian P; Titapun A; Yongvanit P
Tumour Biol; 2017 Jul; 39(7):1010428317717655. PubMed ID: 28671021
[TBL] [Abstract][Full Text] [Related]
56. Estrogen-dependent disruption of intracellular iron metabolism augments the cytotoxic effects of doxorubicin in select breast and ovarian cancer cells.
Bajbouj K; Shafarin J; Hamad M
Cancer Manag Res; 2019; 11():4655-4668. PubMed ID: 31213891
[No Abstract] [Full Text] [Related]
57. Oxidation-Induced Degradable Nanogels for Iron Chelation.
Liu Z; Wang Y; Purro M; Xiong MP
Sci Rep; 2016 Feb; 6():20923. PubMed ID: 26868174
[TBL] [Abstract][Full Text] [Related]
58. Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells.
Ye Z; Connor JR
Biochem Biophys Res Commun; 1999 Nov; 264(3):709-13. PubMed ID: 10543996
[TBL] [Abstract][Full Text] [Related]
59. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis.
Sow FB; Florence WC; Satoskar AR; Schlesinger LS; Zwilling BS; Lafuse WP
J Leukoc Biol; 2007 Oct; 82(4):934-45. PubMed ID: 17609338
[TBL] [Abstract][Full Text] [Related]
60. The iron chelator deferoxamine decreases myeloma cell survival.
Yang F; Wu Z; Dai D; Zhang L; Zhang X; Zhang X; Xu Y
J Int Med Res; 2021 Jan; 49(1):300060520987396. PubMed ID: 33478296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
